An Opportunity to improve measurement of health related quality of life symptoms using MPN Patient reported outcomes

blood test results mpn

A Patient’s Perspective – Methods to Improve MPN Research by Collecting data and Blood test results from Patients by David Wallace As a PV patient, my treatment has run a wide spectrum during the last 6 years.  Starting with phlebotomy only, Hydroxyurea (short time frame), Pegasys (nearing 2 years) and now the “cutting edge combo” […]

Imetelstat Active in Myeloproliferative Disorders

Drug Active in Myeloproliferative Disorders

Essential thrombocythemia, myelofibrosis respond to telomere targeting Treatment with a drug that targets the chromosome-lengthening enzyme telomerase led to hematologic responses in all treated patients with essential thrombocythemia, a preliminary clinical trial showed. In 16 of 18 cases, patients achieved complete hematologic responses with imetelstat. Additionally, seven of eight patients with Janus kinase 2 (JAK2) […]

Jakafi One Step Closer to Approval for Polycythemia Vera

Jakafi for Polycythemia Vera

Jakafi Improves Symptoms in PV In phase 3 randomized controlled trial, Jakafi (ruxolitinib) improved several key symptoms in polycythemia vera, according to Dr Srdan Verstovsek of MD Anderson Cancer Center in Houston. Results from the RESPONSE trial were presented at the 2014 ASCO (American Society of Clinical Oncology) annual meeting in Chicago.  PV is a […]

Emerging Drugs for Polycythemia Vera

pegasys MPN

Polycythem Vera – Expert Opinion on Emerging Drugs Raoul Tibes, Ruben A Mesa Mayo College of Medicine, Mayo Clinic, Mayo Clinic Cancer Center, Division of Hematology & Medical Oncology , 13400 E. Shea Boulevard, Scottsdale, AZ 85259 , USA +1 480 301 6740 ; +1 480 301 4675 ; . Expert Opinion on Emerging Drugs (Impact Factor: […]

error: Content is protected !
Malcare WordPress Security